RGS9 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 8 of 8 results for "RGS9"
i
  1. NM_003835.3(RGS9):c.895T>C (p.Trp299Arg) AND Prolonged electroretinal response suppression ClinVar

    Type: Variation

    Species: human

  2. NM_003835.3(RGS9):c.1645C>T (p.Arg549Cys) AND not provided ClinVar

    Type: single nucleotide variant

    Species: human

  3. NM_003835.3(RGS9):c.1502G>A (p.Arg501His) AND not specified ClinVar

    Type: single nucleotide variant

    Species: human

  4. NM_003835.3(RGS9):c.773C>T (p.Ser258Leu) AND not provided ClinVar

    Type: single nucleotide variant

    Species: human

  5. NM_003835.3(RGS9):c.704C>T (p.Ala235Val) AND not provided ClinVar

    Type: Variation

    Species: human

  6. NM_003835.3(RGS9):c.313_314delACinsGG (p.Thr105Gly) AND not provided ClinVar

    Type: Indel

    Species: human

  7. NM_003835.3(RGS9):c.1658T>C (p.Val553Ala) AND not provided ClinVar

    Type: single nucleotide variant

    Species: human

  8. A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia dbGaP

    ID: phs000594.v1.p1

    Description: LGL leukemia can be divided into three subsets including the following: αβ or γδT-LGL and NK-LGL leukemia. All three subtypes will...

    study.selectionCriteria: arnib previously or with other inhibitors of MAPK signaling intermediates
  9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib. Tipifarnib is contraindicated in individuals with allergies to imidazoles such as clotrimazole, ketoconazole, miconazole, econazaole, fenticonazole, isoconazole, sulconazole, tioconazole, or terconazole. Information regarding possible drug allergies should be obtained from both patient questionnaires and past-medical records
  10. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  11. Women who are pregnant
  12. Women who are breastfeeding
  13. Women of childbearing potential who will not agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  14. Men who will not agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  15. Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. HIV-positive patients receiving anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with tipifarnib, but HIV-positive patients receiving no retroviral therapy may be included in the study
  16. Patients with psychiatric illness/social situations that would limit compliance with study requirements and that would prevent informed decisions regarding entry into the study are excluded from study participation
  17. Patients with γδ T LGL that are positive for iso-chromosome 7, as determined by FISH analysis
  18. ...

Displaying 8 of 8 results for "RGS9"